Haarmann, Helge

[["dc.bibliographiccitation.journal","Pacing and Clinical Electrophysiology"],["dc.contributor.author","Schlögl, Simon"],["dc.contributor.author","Schlögl, Klaudia Stella"],["dc.contributor.author","Haarmann, Helge"],["dc.contributor.author","Bengel, Philipp"],["dc.contributor.author","Bergau, Leonard"],["dc.contributor.author","Rasenack, Eva"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Zabel, Markus"],["dc.date.accessioned","2021-12-01T09:21:15Z"],["dc.date.available","2021-12-01T09:21:15Z"],["dc.date.issued","2021"],["dc.identifier.doi","10.1111/pace.14392"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/94387"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-478"],["dc.relation.eissn","1540-8159"],["dc.relation.issn","0147-8389"],["dc.title","Remote magnetic navigation versus manual catheter ablation of atrial fibrillation: A single center long‐term comparison"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","589"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","COPD: Journal of Chronic Obstructive Pulmonary Disease"],["dc.bibliographiccitation.lastpage","594"],["dc.bibliographiccitation.volume","13"],["dc.contributor.author","Haarmann, Helge"],["dc.contributor.author","Folle, Jan"],["dc.contributor.author","Xuan Phuc Nguyen, Xuan Phuc Nguyen"],["dc.contributor.author","Herrmann, Peter"],["dc.contributor.author","Heusser, Karsten"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Andreas, Stefan"],["dc.contributor.author","Raupach, Tobias"],["dc.date.accessioned","2017-09-07T11:54:43Z"],["dc.date.available","2017-09-07T11:54:43Z"],["dc.date.issued","2016"],["dc.description.abstract","Exercise intolerance, skeletal muscle dysfunction, and reduced daily activity are central in COPD patients and closely related to quality of life and prognosis. Studies assessing muscle exercise have revealed an increase in sympathetic outflow as a link to muscle hypoperfusion and exercise limitation. Our primary hypothesis was that muscle sympathetic nerve activity (MSNA) correlates with exercise limitation in COPD. MSNA was evaluated at rest and during dynamic or static handgrip exercise. Additionally, we assessed heart rate, blood pressure, CO2 tension, oxygen saturation (SpO(2)), and breathing frequency. Ergospirometry was performed to evaluate exercise capacity. We assessed MSNA of 14 COPD patients and 8 controls. In patients, MSNA was negatively correlated with peak oxygen uptake (VO2 % pred) (r = -0.597; p = 0.040). During dynamic or static handgrip exercise, patients exhibited a significant increase in MSNA, which was not observed in the control group. The increase in MSNA during dynamic handgrip was highly negatively correlated with peak exercise capacity in Watts (w) and peak oxygen uptake (VO2/kg) (r = -0.853; p = 0.002 and r = -0.881; p = 0.002, respectively). Our study reveals an association between increased MSNA and limited exercise capacity in patients with COPD. Furthermore, we found an increased sympathetic response to moderate physical exercise (handgrip), which may contribute to exercise intolerance in COPD."],["dc.identifier.doi","10.3109/15412555.2015.1136272"],["dc.identifier.gro","3141749"],["dc.identifier.isi","000381997300009"],["dc.identifier.pmid","26829234"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/646"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Taylor & Francis Inc"],["dc.relation.eissn","1541-2563"],["dc.relation.issn","1541-2555"],["dc.title","Sympathetic Activation is Associated with Exercise Limitation in COPD"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Journal of Interventional Cardiac Electrophysiology"],["dc.contributor.author","Schlögl, Simon"],["dc.contributor.author","Schlögl, Klaudia Stella"],["dc.contributor.author","Bengel, Philipp"],["dc.contributor.author","Bergau, Leonard"],["dc.contributor.author","Haarmann, Helge"],["dc.contributor.author","Rasenack, Eva"],["dc.contributor.author","Hasenfuss, Gerd"],["dc.contributor.author","Zabel, Markus"],["dc.date.accessioned","2022-09-01T09:49:21Z"],["dc.date.available","2022-09-01T09:49:21Z"],["dc.date.issued","2022"],["dc.description.abstract","Abstract\n \n Background\n In atrial fibrillation (AF) patients, catheter ablation of pulmonary veins (PVI) is the most effective therapeutic option to maintain sinus rhythm. To improve successful PVI, contact force–sensing (CF) catheters became routinely available. Previous studies did not clearly show superior clinical efficacy in comparison with non-CF catheters.\n \n \n Methods\n We investigated consecutive patients, who underwent index PVI for AF at our hospital between 2012 and 2018. Three hundred and fifty-four patients were ablated without CF. After availability of CF catheters in 2016, 317 patients were ablated using CF. In case of crossover between the groups, follow-up was censored. The primary endpoint was any documented atrial tachycardia (AT) or atrial fibrillation > 30 s after a 3-month blanking period. Secondary endpoints were procedural characteristics and periprocedural complications.\n \n \n Results\n \n There was no significant difference between the groups at baseline except hyperlipidemia. After 365 days of follow-up, 67% of patients in the CF group remained free from AF/AT recurrence compared to 59% in non-CF group (\n P\n  = 0.038). In multivariable Cox regression analysis, non-CF ablation was an independent risk factor for AF recurrence besides age and persistent AF. Total fluoroscopy time (15 ± 7.6 vs. 28 ± 15.9 min) and total procedure time (114 ± 29.6 vs. 136 ± 38.5 min) were significantly lower for CF-guided PVI (\n P\n  < 0.001). Complication rates did not differ between groups (\n P\n  = 0.661).\n \n \n \n Conclusions\n In our study, the AT/AF recurrence rate and pulmonary vein reconnection rate is lower after CF PVI with a similar complication rate but lower total procedure time and total fluoroscopy time compared to non-CF PVI."],["dc.identifier.doi","10.1007/s10840-022-01316-8"],["dc.identifier.pii","1316"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/113401"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-597"],["dc.relation.eissn","1572-8595"],["dc.relation.issn","1383-875X"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Impact of open-irrigated radiofrequency catheter with contact force measurement on the efficacy and safety of atrial fibrillation ablation: a single-center direct comparison"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","46"],["dc.bibliographiccitation.journal","BMC Pulmonary Medicine"],["dc.bibliographiccitation.volume","15"],["dc.contributor.author","Haarmann, Helge"],["dc.contributor.author","Mohrlang, Cordula"],["dc.contributor.author","Tschiesner, Uta"],["dc.contributor.author","Rubin, David B."],["dc.contributor.author","Bornemann, Thore"],["dc.contributor.author","Rueter, Karin"],["dc.contributor.author","Bonev, Slavtcho"],["dc.contributor.author","Raupach, Tobias"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Andreas, Stefan"],["dc.date.accessioned","2017-09-07T11:44:26Z"],["dc.date.available","2017-09-07T11:44:26Z"],["dc.date.issued","2015"],["dc.description.abstract","Background: Neurohumoral activation is present in COPD and might provide a link between pulmonary and systemic effects, especially cardiovascular disease. Because long acting inhaled beta-agonists reduce hyperinflation, they could reduce sympathoexcitation by improving the inflation reflex. We aimed to evaluate if inhaled therapy with salmeterol reduces muscle sympathetic nerve activity (MSNA) evaluated by microneurography. Methods: MSNA, heart rate, blood pressure, and respiration were continually measured. After baseline recording of 20 minutes, placebo was administered; after further 45 minutes salmeterol (50 mu g) was administered which was followed by a further 45 minutes of data recording. Additionally, lung function, plasma catecholamine levels, arterial pulse wave velocity, heart rate variability, and baroreflex sensitivity were evaluated. Following 4 weeks of treatment with salmeterol 50 mu g twice daily, measurements were repeated without placebo administration. Results: A total of 32 COPD patients were included. Valid MSNA signals were obtained from 18 patients. Change in MSNA (bursts/100 heart beats) following acute administration of salmeterol did not differ significantly from the change following placebo (-1.96 +/- 9.81 vs. -0.65 +/- 9.07; p = 0.51) although hyperinflation was significantly reduced. Likewise, no changes in MSNA or catecholamines were observed after 4 weeks. Heart rate increased significantly by 3.8 +/- 4.2 (p < 0.01) acutely and 3.9 +/- 4.3 bpm (p < 0.01) after 4 weeks. Salmeterol treatment was safe and well tolerated. Conclusions: By using microneurography as a gold standard to evaluate sympathetic activity we found no change in MSNA following salmeterol inhalation. Thus, despite an attenuation of hyperinflation, the long acting beta-agonist salmeterol does not appear to reduce nor incite sympathoexcitation."],["dc.identifier.doi","10.1186/s12890-015-0054-7"],["dc.identifier.gro","3141919"],["dc.identifier.isi","000356211900001"],["dc.identifier.pmid","25924990"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/12294"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/2533"],["dc.notes.intern","WoS Import 2017-03-10 / Funder: GlaxoSmithKline, Munich, Germany [SCO114520]"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1471-2466"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Inhaled beta-agonist does not modify sympathetic activity in patients with COPD"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","3437"],["dc.bibliographiccitation.issue","36"],["dc.bibliographiccitation.journal","European Heart Journal"],["dc.bibliographiccitation.lastpage","3447"],["dc.bibliographiccitation.volume","41"],["dc.contributor.author","Zabel, Markus"],["dc.contributor.author","Willems, Rik"],["dc.contributor.author","Lubinski, Andrzej"],["dc.contributor.author","Bauer, Axel"],["dc.contributor.author","Brugada, Josep"],["dc.contributor.author","Conen, David"],["dc.contributor.author","Flevari, Panagiota"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Harden, Markus"],["dc.contributor.author","Friede, Tim"],["dc.contributor.author","Zabel, Markus"],["dc.contributor.author","Lüthje, Lars"],["dc.contributor.author","Haarmann, Helge"],["dc.contributor.author","Bergau, Leonard"],["dc.contributor.author","Tichelbäcker, Tobias"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Friede, Tim"],["dc.contributor.author","Zabel, Markus"],["dc.contributor.author","Friede, Tim"],["dc.contributor.author","Harden, Markus"],["dc.contributor.author","Pieske, Burkert"],["dc.contributor.authorgroup","EU-CERT-ICD Study Investigators"],["dc.date.accessioned","2020-05-07T07:50:46Z"],["dc.date.accessioned","2021-10-27T13:22:10Z"],["dc.date.available","2020-05-07T07:50:46Z"],["dc.date.available","2021-10-27T13:22:10Z"],["dc.date.issued","2020"],["dc.description.abstract","Aims: The EUropean Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter-Defibrillators (EU-CERT-ICD), a prospective investigator-initiated, controlled cohort study, was conducted in 44 centres and 15 European countries. It aimed to assess current clinical effectiveness of primary prevention ICD therapy. Methods and results: We recruited 2327 patients with ischaemic cardiomyopathy (ICM) or dilated cardiomyopathy (DCM) and guideline indications for prophylactic ICD implantation. Primary endpoint was all-cause mortality. Clinical characteristics, medications, resting, and 12-lead Holter electrocardiograms (ECGs) were documented at enrolment baseline. Baseline and follow-up (FU) data from 2247 patients were analysable, 1516 patients before first ICD implantation (ICD group) and 731 patients without ICD serving as controls. Multivariable models and propensity scoring for adjustment were used to compare the two groups for mortality. During mean FU of 2.4 ± 1.1 years, 342 deaths occurred (6.3%/years annualized mortality, 5.6%/years in the ICD group vs. 9.2%/years in controls), favouring ICD treatment [unadjusted hazard ratio (HR) 0.682, 95% confidence interval (CI) 0.537–0.865, P = 0.0016]. Multivariable mortality predictors included age, left ventricular ejection fraction (LVEF), New York Heart Association class

[["dc.bibliographiccitation.firstpage","1242"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Journal of Cachexia, Sarcopenia and Muscle"],["dc.bibliographiccitation.lastpage","1249"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Haehling, Stephan"],["dc.contributor.author","Garfias Macedo, Tania"],["dc.contributor.author","Valentova, Miroslava"],["dc.contributor.author","Anker, Markus S."],["dc.contributor.author","Ebner, Nicole"],["dc.contributor.author","Bekfani, Tarek"],["dc.contributor.author","Haarmann, Helge"],["dc.contributor.author","Schefold, Joerg C."],["dc.contributor.author","Lainscak, Mitja"],["dc.contributor.author","Cleland, John G. F."],["dc.contributor.author","Doehner, Wolfram"],["dc.contributor.author","Hasenfuss, Gerd"],["dc.contributor.author","Anker, Stefan D."],["dc.date.accessioned","2021-04-14T08:24:54Z"],["dc.date.available","2021-04-14T08:24:54Z"],["dc.date.issued","2020"],["dc.description.abstract","Abstract Background Skeletal muscle wasting is an extremely common feature in patients with heart failure, affecting approximately 20% of ambulatory patients with even higher values during acute decompensation. Its occurrence is associated with reduced exercise capacity, muscle strength, and quality of life. We sought to investigate if the presence of muscle wasting carries prognostic information. Methods Two hundred sixty‐eight ambulatory patients with heart failure (age 67.1 ± 10.9 years, New York Heart Association class 2.3 ± 0.6, left ventricular ejection fraction 39 ± 13.3%, and 21% female) were prospectively enrolled as part of the Studies Investigating Co‐morbidities Aggravating Heart Failure. Muscle wasting as assessed using dual‐energy X‐ray absorptiometry was present in 47 patients (17.5%). Results During a mean follow‐up of 67.2 ± 28.02 months, 95 patients (35.4%) died from any cause. After adjusting for age, New York Heart Association class, left ventricular ejection fraction, creatinine, N‐terminal pro‐B‐type natriuretic peptide, and iron deficiency, muscle wasting remained an independent predictor of death (hazard ratio 1.80, 95% confidence interval 1.01–3.19, P = 0.04). This effect was more pronounced in patients with heart failure with reduced than in heart failure with preserved ejection fraction. Conclusions Muscle wasting is an independent predictor of death in ambulatory patients with heart failure. Clinical trials are needed to identify treatment approaches to this co‐morbidity."],["dc.identifier.doi","10.1002/jcsm.12603"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/17708"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/81461"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-399"],["dc.notes.intern","Merged from goescholar"],["dc.relation.eissn","2190-6009"],["dc.relation.issn","2190-5991"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Muscle wasting as an independent predictor of survival in patients with chronic heart failure"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","69"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Lung"],["dc.bibliographiccitation.lastpage","75"],["dc.bibliographiccitation.volume","195"],["dc.contributor.author","Haarmann, Helge"],["dc.contributor.author","Folle, Jan"],["dc.contributor.author","Nguyen, Xuan Phuc"],["dc.contributor.author","Herrmann, Peter"],["dc.contributor.author","Heusser, Karsten"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Andreas, Stefan"],["dc.contributor.author","Raupach, Tobias"],["dc.date.accessioned","2017-09-07T11:52:35Z"],["dc.date.available","2017-09-07T11:52:35Z"],["dc.date.issued","2016"],["dc.description.abstract","Purpose Chronic obstructive pulmonary disease (COPD) is associated with elevated sympathetic nerve activity, which is probably linked to an increased cardiovascular risk, and may contribute to muscle dysfunction by heightened muscle vasoconstrictor drive. We hypothesized that resistive unloading of respiratory muscles by intermittent non-invasive ventilation (NIV) reduces sympathetic tone at rest and during subsequent handgrip exercise in patients with COPD. Methods Muscle sympathetic nerve activity (MSNA) in the peroneal nerve, heart rate, blood pressure, CO2, and SpO2 were continuously recorded in 5 COPD patients with intermittent NIV and 11 control COPD patients without NIV. Static and dynamic handgrip exercises were performed before and after NIV. Results At baseline, heart rate-adjusted MSNA (bursts/100 heart beats) did not differ between groups. NIV did not significantly affect MSNA levels at rest. However, during handgrip exercises directly following NIV, MSNA was lower than before, which was significant for dynamic handgrip (67.00 ± 3.70 vs. 62.13 ± 4.50 bursts/100 heart beats; p = 0.035 in paired t test). In contrast, MSNA (non-significantly) increased in the control group during repeated dynamic or static handgrip. During dynamic handgrip, tCO2 was lower after NIV than before (change by −5.04 ± 0.68 mmHg vs. −0.53 ± 0.64 in the control group; p = 0.021), while systolic and diastolic blood pressure did not change significantly. Conclusions NIV reduces sympathetic activation during subsequent dynamic handgrip exercise and thereby may elicit positive effects on the cardiovascular system as well as on muscle function in patients with COPD."],["dc.identifier.doi","10.1007/s00408-016-9965-1"],["dc.identifier.gro","3144961"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/2643"],["dc.language.iso","en"],["dc.notes.intern","Crossref Import"],["dc.notes.status","final"],["dc.relation.issn","0341-2040"],["dc.title","Impact of Non-Invasive Ventilation on Sympathetic Nerve Activity in Chronic Obstructive Pulmonary Disease"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","no"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","235"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Lung"],["dc.bibliographiccitation.lastpage","241"],["dc.bibliographiccitation.volume","192"],["dc.contributor.author","Andreas, Stefan"],["dc.contributor.author","Haarmann, Helge"],["dc.contributor.author","Klarner, Stephan"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Raupach, Tobias"],["dc.date.accessioned","2017-09-07T11:46:22Z"],["dc.date.available","2017-09-07T11:46:22Z"],["dc.date.issued","2014"],["dc.description.abstract","Chronic obstructive lung disease (COPD) is a major cause of comorbidity and mortality. Systemic effects, such as sympathetic activation, might contribute to progression and severity of the disease. This study investigated whether increased sympathetic activity is associated with increased long-term morbidity and mortality with COPD. Following a baseline registration of muscle sympathetic nerve activity (MSNA), 21 COPD patients and 21 matched healthy control subjects were contacted after a mean follow-up period of 7 years. Information about the number of hospitalizations during follow-up was obtained from patients who were still alive. Information about the time of death was collected from relatives of the deceased and local registration offices. The primary endpoint was the comparison of MSNA in living patients without hospitalizations versus MSNA in the patients who died or had at least one hospitalization due to exacerbation of COPD. At baseline, MSNA was significantly increased, whereas forced expiratory volume in 1 s and arterial oxygen tension (PaO2) were significantly decreased in patients compared with controls. MSNA was significantly higher in COPD patients who had reached the combined endpoint of hospitalization or death during follow-up (n = 12) compared with patients who were still alive at follow-up and had not been hospitalized (n = 8): 60.3 +/- A 15.8 (SD) bursts/min versus 40.5 +/- A 17.5 bursts/min; p = 0.022. Our data suggest that sympathetic activation is related to adverse outcome in COPD. Although this finding has to be replicated in larger studies, it implies that neurohumoral activation could be a potential therapeutic target in COPD."],["dc.identifier.doi","10.1007/s00408-013-9544-7"],["dc.identifier.gro","3142160"],["dc.identifier.isi","000333122400003"],["dc.identifier.pmid","24362752"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/5199"],["dc.notes.intern","WoS Import 2017-03-10"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Springer"],["dc.relation.eissn","1432-1750"],["dc.relation.issn","0341-2040"],["dc.title","Increased Sympathetic Nerve Activity in COPD is Associated with Morbidity and Mortality"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","S34"],["dc.bibliographiccitation.journal","Journal of Electrocardiology"],["dc.bibliographiccitation.lastpage","S39"],["dc.bibliographiccitation.volume","57"],["dc.contributor.author","Zabel, Markus"],["dc.contributor.author","Schlögl, Simon"],["dc.contributor.author","Lubinski, Andrzej"],["dc.contributor.author","Svendsen, Jesper Hastrup"],["dc.contributor.author","Bauer, Axel"],["dc.contributor.author","Arbelo, Elena"],["dc.contributor.author","Brusich, Sandro"],["dc.contributor.author","Conen, David"],["dc.contributor.author","Cygankiewicz, Iwona"],["dc.contributor.author","Dommasch, Michael"],["dc.contributor.author","Flevari, Panagiota"],["dc.contributor.author","Galuszka, Jan"],["dc.contributor.author","Hansen, Jim"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Hatala, Robert"],["dc.contributor.author","Huikuri, Heikki V."],["dc.contributor.author","Kenttä, Tuomas"],["dc.contributor.author","Kucejko, Tomasz"],["dc.contributor.author","Haarmann, Helge"],["dc.contributor.author","Harden, Markus"],["dc.contributor.author","Iovev, Svetoslav"],["dc.contributor.author","Kääb, Stefan"],["dc.contributor.author","Kaliska, Gabriela"],["dc.contributor.author","Katsimardos, Andreas"],["dc.contributor.author","Kasprzak, Jaroslaw D."],["dc.contributor.author","Qavoq, Dariusz"],["dc.contributor.author","Lüthje, Lars"],["dc.contributor.author","Malik, Marek"],["dc.contributor.author","Novotný, Tomáš"],["dc.contributor.author","Pavlović, Nikola"],["dc.contributor.author","Perge, Peter"],["dc.contributor.author","Röver, Christian"],["dc.contributor.author","Schmidt, Georg"],["dc.contributor.author","Shalganov, Tchavdar"],["dc.contributor.author","Sritharan, Rajeeva"],["dc.contributor.author","Svetlosak, Martin"],["dc.contributor.author","Sallo, Zoltan"],["dc.contributor.author","Szavits-Nossan, Janko"],["dc.contributor.author","Traykov, Vassil"],["dc.contributor.author","Vandenberk, Bert"],["dc.contributor.author","Velchev, Vasil"],["dc.contributor.author","Vos, Marc A."],["dc.contributor.author","Willich, Stefan N."],["dc.contributor.author","Friede, Tim"],["dc.contributor.author","Willems, Rik"],["dc.contributor.author","Merkely, Béla"],["dc.contributor.author","Sticherling, Christian"],["dc.date.accessioned","2020-12-10T14:25:06Z"],["dc.date.available","2020-12-10T14:25:06Z"],["dc.date.issued","2019"],["dc.identifier.doi","10.1016/j.jelectrocard.2019.09.001"],["dc.identifier.issn","0022-0736"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/16386"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/72436"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.notes.intern","Merged from goescholar"],["dc.rights","Goescholar"],["dc.rights.uri","https://goescholar.uni-goettingen.de/licenses"],["dc.title","Present criteria for prophylactic ICD implantation: Insights from the EU-CERT-ICD (Comparative Effectiveness Research to Assess the Use of Primary ProphylacTic Implantable Cardioverter Defibrillators in EUrope) project"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.version","submitted_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","26"],["dc.bibliographiccitation.journal","Tobacco Induced Diseases"],["dc.bibliographiccitation.volume","14"],["dc.contributor.author","Haarmann, Helge"],["dc.contributor.author","Gossler, Alexandra"],["dc.contributor.author","Herrmann, Peter"],["dc.contributor.author","Bonev, Slavtcho"],["dc.contributor.author","Xuan Phuc Nguyen, Xuan Phuc Nguyen"],["dc.contributor.author","Hasenfuß, Gerd"],["dc.contributor.author","Andreas, Stefan"],["dc.contributor.author","Raupach, Tobias"],["dc.date.accessioned","2017-09-07T11:44:44Z"],["dc.date.available","2017-09-07T11:44:44Z"],["dc.date.issued","2016"],["dc.description.abstract","Background: Varenicline is an effective smoking cessation medication. Some concern has been raised that its use may precipitate adverse cardiovascular events although no patho-physiological mechanism potentially underlying such an effect has been reported. The aim of this study was to test the hypothesis that varenicline impacts on sympatho-vagal balance during smoking withdrawal. Methods: In this randomised, placebo-controlled trial, muscle sympathetic nerve activity (MSNA), baroreflex sensitivity (BRS), heart rate, and blood pressure were assessed in 17 smokers four weeks before a quit attempt (baseline) and again on the third day of that quit attempt (acute smoking withdrawal). Results: Regarding the primary endpoint of our study, we did not find a significant effect of varenicline compared to placebo on changes in MSNA burst incidence between baseline and acute smoking withdrawal (-3.0 +/- 3.3 vs.-3.9 +/- 5.0 bursts/100 heart beats; p = 0.308). However, heart rate and systolic blood pressure significantly decreased in the placebo group only, while no significant changes in these parameters were observed in the varenicline group. Exposure to smoking cues during acute withdrawal lead to a significant increase of heart rate in the placebo group, while heart rate decreased in the varenicline group, and the difference in these changes was significant between groups (+ 2.7 +/- 1.0 vs.-1.8 +/- 0.5 1/min; p = 0.002). In all 17 participants combined, a significant increase in heart rate during smoking cue exposure was detected in subjects who relapsed in the course of six weeks after the quit date compared to those who stayed abstinent (+ 2.5 +/- 1.2 vs.-1.1 +/- 0.7; p = 0.018). Six-week abstinence rates were higher in the varenicline group compared to placebo (88 vs. 22 % p = 0.015). Conclusion: We did not find evidence of adverse effects of varenicline on sympatho-vagal balance. Varenicline probably blunts the heart rate response to smoking cues, which may be linked to improved cessation outcome."],["dc.identifier.doi","10.1186/s12971-016-0091-x"],["dc.identifier.gro","3141637"],["dc.identifier.isi","000381574200001"],["dc.identifier.pmid","27507930"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/13863"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/3900"],["dc.notes.intern","WoS Import 2017-03-10 / Funder: Pfizer(R)"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","final"],["dc.notes.submitter","PUB_WoS_Import"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1617-9625"],["dc.rights","CC BY 4.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/4.0"],["dc.title","Effects of varenicline on sympatho-vagal balance and cue reactivity during smoking withdrawal: a randomised placebo-controlled trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.subtype","original"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]